Cargando…

Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists

[Image: see text] While screening off-target effects of rigid (N)-methanocarba-adenosine 5′-methylamides as A(3) adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). In an effort to increase OR and decrease AR affinity by str...

Descripción completa

Detalles Bibliográficos
Autores principales: Tosh, Dilip K., Ciancetta, Antonella, Mannes, Philip, Warnick, Eugene, Janowsky, Aaron, Eshleman, Amy J., Gizewski, Elizabeth, Brust, Tarsis F., Bohn, Laura M., Auchampach, John A., Gao, Zhan-Guo, Jacobson, Kenneth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210068/
https://www.ncbi.nlm.nih.gov/pubmed/30411015
http://dx.doi.org/10.1021/acsomega.8b01237
_version_ 1783367033512001536
author Tosh, Dilip K.
Ciancetta, Antonella
Mannes, Philip
Warnick, Eugene
Janowsky, Aaron
Eshleman, Amy J.
Gizewski, Elizabeth
Brust, Tarsis F.
Bohn, Laura M.
Auchampach, John A.
Gao, Zhan-Guo
Jacobson, Kenneth A.
author_facet Tosh, Dilip K.
Ciancetta, Antonella
Mannes, Philip
Warnick, Eugene
Janowsky, Aaron
Eshleman, Amy J.
Gizewski, Elizabeth
Brust, Tarsis F.
Bohn, Laura M.
Auchampach, John A.
Gao, Zhan-Guo
Jacobson, Kenneth A.
author_sort Tosh, Dilip K.
collection PubMed
description [Image: see text] While screening off-target effects of rigid (N)-methanocarba-adenosine 5′-methylamides as A(3) adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). In an effort to increase OR and decrease AR affinity by structure activity analysis of this series, antagonist activity at κ-(K)OR appeared in 5′-esters (ethyl 24 and propyl 30), which retained TSPO interaction (μM). 7-Deaza modification of C2-(arylethynyl)-5′-esters but not 4′-truncation enhanced KOR affinity (MRS7299 28 and 29, K(i) ≈ 40 nM), revealed μ-OR and DOR binding, and reduced AR affinity. Molecular docking and dynamics simulations located a putative KOR binding mode consistent with the observed affinities, placing C7 in a hydrophobic region. 3-Deaza modification permitted TSPO but not OR binding, and 1-deaza was permissive to both; ribose-restored analogues were inactive at both. Thus, we have repurposed a known AR nucleoside scaffold for OR antagonism, with a detailed hypothesis for KOR recognition.
format Online
Article
Text
id pubmed-6210068
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-62100682018-11-06 Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists Tosh, Dilip K. Ciancetta, Antonella Mannes, Philip Warnick, Eugene Janowsky, Aaron Eshleman, Amy J. Gizewski, Elizabeth Brust, Tarsis F. Bohn, Laura M. Auchampach, John A. Gao, Zhan-Guo Jacobson, Kenneth A. ACS Omega [Image: see text] While screening off-target effects of rigid (N)-methanocarba-adenosine 5′-methylamides as A(3) adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). In an effort to increase OR and decrease AR affinity by structure activity analysis of this series, antagonist activity at κ-(K)OR appeared in 5′-esters (ethyl 24 and propyl 30), which retained TSPO interaction (μM). 7-Deaza modification of C2-(arylethynyl)-5′-esters but not 4′-truncation enhanced KOR affinity (MRS7299 28 and 29, K(i) ≈ 40 nM), revealed μ-OR and DOR binding, and reduced AR affinity. Molecular docking and dynamics simulations located a putative KOR binding mode consistent with the observed affinities, placing C7 in a hydrophobic region. 3-Deaza modification permitted TSPO but not OR binding, and 1-deaza was permissive to both; ribose-restored analogues were inactive at both. Thus, we have repurposed a known AR nucleoside scaffold for OR antagonism, with a detailed hypothesis for KOR recognition. American Chemical Society 2018-10-04 /pmc/articles/PMC6210068/ /pubmed/30411015 http://dx.doi.org/10.1021/acsomega.8b01237 Text en Copyright © 2018 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Tosh, Dilip K.
Ciancetta, Antonella
Mannes, Philip
Warnick, Eugene
Janowsky, Aaron
Eshleman, Amy J.
Gizewski, Elizabeth
Brust, Tarsis F.
Bohn, Laura M.
Auchampach, John A.
Gao, Zhan-Guo
Jacobson, Kenneth A.
Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
title Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
title_full Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
title_fullStr Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
title_full_unstemmed Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
title_short Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
title_sort repurposing of a nucleoside scaffold from adenosine receptor agonists to opioid receptor antagonists
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210068/
https://www.ncbi.nlm.nih.gov/pubmed/30411015
http://dx.doi.org/10.1021/acsomega.8b01237
work_keys_str_mv AT toshdilipk repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists
AT ciancettaantonella repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists
AT mannesphilip repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists
AT warnickeugene repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists
AT janowskyaaron repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists
AT eshlemanamyj repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists
AT gizewskielizabeth repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists
AT brusttarsisf repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists
AT bohnlauram repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists
AT auchampachjohna repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists
AT gaozhanguo repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists
AT jacobsonkennetha repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists